In 2019, the FDA approved the treatment of pembrolizumab (Keytruda) and lenvatinib (Lenvima) as a second-line or third-line treatment for patients with advanced, metastatic, or recurrent endometrial cancer not amenable to curative surgery or radiation therapy whose disease is not microsatellite instability-high or mismatch repair deficient (a genetic condition associated with impaired or poorly functioning DNA).
Initially, pembrolizumab was approved as a monotherapy for patients with microsatellite instability-high recurrent endometrial cancer. However, in the KEYNOTE-775 study, 827 endometrial cancer patients were treated with either pembrolizumab and lenvatinib or physician’s choice (e.g., chemotherapy). The median progression-free survival for the patients treated with pembrolizumab and lenvatinib was 6.6 months vs 3.8 months for the patients treated with chemotherapy. Correspondingly, median overall survival was 17.4 months for the patients treated with pembrolizumab and lenvatinib vs 12.0 months for the patients treated with chemotherapy. The safety profile of pembrolizumab and lenvatinib was generally consistent with the established safety profiles of single agent therapies.
About Women’s Cancer Research Foundation The Women’s Cancer Research Foundation (WCRF) is one of Southern California’s and the nation’s most active research organizations for female cancers. We are dedicated to serving the interests of patients, families, and friends affected by women’s cancers. WCRF partners with physician-scientists nationally to make differences in women’s lives by offering hope, strength, and progress.
361 Hospital Road, Suite 422
Newport Beach, CA 92663
PH: (949) 642-5165